Summary
The plasma pharmacokinetics of pantoprazole have been investigated following single intravenous infusion and single oral administration at a dose of 40 mg to 12 healthy male subjects in a randomised cross-over study.
Both treatments were generally well tolerated and no relevant compound-related adverse events were noted. The plasma pharmacokinetics of pantoprazole following intravenous infusion in this group of subjects were characterised by a total plasma clearance of 0.13 l·h−1·kg−1 and apparent terminal elimination half-life 1.9 h. The apparent volume of distribution estimated at steady state (0.171·kg−1) was compatible with the localization of a major fraction of the compound in extracellular water. Following oral administration as an enteric-coated tablet formulation, a variable onset of absorption was followed by rapid attainment of maximum plasma concentrations of pantoprazole.
Pantoprazole was well absorbed following oral administration; the absolute systemic bioavailability of the compound was estimated as 77% (95% CI, 67 to 89%).
Article PDF
Similar content being viewed by others
References
Simon WA, Keeling DJ, Laing SM, Fallowfield C, Taylor AG (1990) BY 1023/SK&F96022: biochemistry of a novel (H++K+)-ATPase inhibitor. Biochem Pharmacol 39: 1799–1806
Simon B, Müller P, Bliesath H, Lühmann R, Hartmann M, Huber R, Wurst W (1990) Single intravenous administration of the H+, K+-ATPase inhibitor BY 1023/SK&F 96022 — inhibition of pentagastrin-stimulated gastric acid secretion and pharmacokinetics in man. Aliment Pharmacol Ther 4: 239–245
Figala V, Klemm K, Kohl B, Krüger U, Rainer G, Schaefer H, Senn-Bilfinger J, Sturm E (1986) Acid activation of (H+-K+)-ATPase inhibiting 2-(2-pyridylethyl-sulphinyl)benzimidazoles: isolation and characterisation of the thiophilic ‘active principle’ and its reactions. J Chem Soc Chem Commun 125–127
Chiou WL (1978) Critical evaluation of the potential error in pharmacokinetic studies of using the linear trapezoidal rule method for the calculation of the area under the plasma level-time curve. J Pharmacokinet Biopharm 6: 539–546
Rowland M, Tozer TN (1989) Clinical pharmacokinetics: concepts and applications. Lea&Febinger, Philadelphia
Howden CW, Meredith PA, Forrest JAH, Reid JL (1984) Oral pharmacokinetics of omeprazole. Eur J Clin Pharmacol 26: 641–643
Regårdh CG, Andersson T, Lagerström PO, Lundberg P, Skånberg I (1990) The pharmacokinetics of omeprazole in humans. A study of single intravenous and oral doses. Ther Drug Monit 12: 163–172
Andersson T, Cederberg C, Edvardsson G, Heggelund A Lundborg P (1990) Effect of omeprazole treatment on diazepam plasma levels in slow versus normal rapid metabolizers of omeprazole. Clin Pharmacol Ther 47: 79–85
Andersson T, Regårdh CG, Dahl-Puustinen ML, Bertilsson L (1990) Slow omeprazole metabolizers are also poor S-mephenytoin hyroxylators. Ther Drug Monit 12: 415–416
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Pue, M.A., Laroche, J., Meineke, I. et al. Pharmacokinetics of pantoprazole following single intravenous and oral administration to healthy male subjects. Eur J Clin Pharmacol 44, 575–578 (1993). https://doi.org/10.1007/BF02440862
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF02440862